Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Squamous Cell
The combination of weekly cisplatin plus irinotecan had significant activity in metastatic esophageal carcinoma and resulted in significant relief of dysphagia. The regimen was well tolerated, with acceptable myelosuppression and rare treatment-related diarrhea. Further evaluation of the combination of weekly irinotecan and cisplatin, including the addition of other agents to this regimen, is indicated.